Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03117166 · ClinicalTrials.gov registry record · Phase 1

Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

A Phase 1 study, sponsored by Drexel University College of Medicine.

Terminated
Registry status
Phase 1
Development phase
19
Enrollment target

NCT03117166 is a Phase 1 study that was terminated before completion, run by Drexel University College of Medicine. The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03117166, a Phase 1 study, was terminated before completion, sponsored by Drexel University College of Medicine.

TERMINATED
Registry status
Phase 1
Development phase
19 participants
Enrollment target

Study Summary

The use of lidocaine, as an anesthetic drug, during implantation of an implantable cardioverter-defibrillator(ICD)will not result in a clinically significant alteration of the defibrillation threshold during ICD placement.

Interventions

  • DRUG Placebo
  • DRUG lidocaine

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2010-01
Est. Completion 2010-05
Phase Phase 1

What the Registry Record Tells You About NCT03117166

The ClinicalTrials.gov registry entry for NCT03117166 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Drexel University College of Medicine, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03117166 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03117166 about?

NCT03117166 is a clinical study titled "Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing". The use of lidocaine, as an anesthetic drug, during implantation of an implantable cardioverter-defibrillator(ICD)will not result in a clinically significant alteration of the defibrillation threshold during ICD placement.

What is the current status of trial NCT03117166?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2010-01. Estimated completion is 2010-05.

What interventions are being tested in trial NCT03117166?

The interventions under investigation include: Placebo (DRUG), lidocaine (DRUG).

Who is sponsoring clinical trial NCT03117166?

This trial is sponsored by Drexel University College of Medicine, which has 25 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.